GENERAL COMMENTS
It is an interesting open-label, non-controlled, multicenter clinical trial using three doses of FT in the treatment of acute uncomplicated cystitis, recurrent UTI or complicated UTI. I have only a few questions/comments. 1) From exclusion criteria we learn that acute pyelonephritis or acute episode (better than bout) of chronic pyelonephritis were not included. Therefore I suggest a more specific terminology in: Page 3, lines 19/21; page 4, line 6 and 37/39; page 7, lines 9/11; page 18, line 4; such as "….patients with acute uncomplicated cystitis, recurrent lower UTI or complicated lower UTI" (lower should be added because pyelonephritis was excluded). Page 3, line 9: "…to treat lower urinary tract infections…" (lower should be added as well) 2)Microbiological efficacy: it is completely unusual to consider "partially cleared" as an "effective" result. By change, no patient felt into this category.Therefore, I suggest to skip the category "partially cleared" and include this category into "not cleared".
To categorize "replacement" or "reinfection" also as effective therapy is sometimes done, but to my opinion not correct, because it is an "unwanted" outcome. Therefore I suggest to reorganize Table 3 as follows:
By the way: the usual terminology is for cleared-eradication and for not cleared persistence. Usually for other bacteria only the term reinfection is used, but I like the differentiation between replacement without symptoms and reinfection with symptoms. Therefore the two terms should be used, but could be summarized in the table ( or not, whatever the authors like better).
As limitation of the study it should also be mentioned that the study is not controlled. All in all, the study is well performed and presented. From exclusion criteria we learn that acute pyelonephritis or acute episode (better than bout) of chronic pyelonephritis were not included. Therefore I suggest a more specific terminology in: Page 3, lines19/21; page 4, line 6 and 37/39; page 7, lines 9/11; page 18, line 4; such as "….patients with acute uncomplicated cystitis, recurrent lower UTI or complicated lower UTI" (lower should be added because pyelonephritis was excluded). Page 3, line 9: "…to treat lower urinary tract infections…" (lower should be added as well) Response: to define more specifically the UTIs described in this study, the term "lower" was added where applicable. Also, "bout" was changed to "episode" as suggested. 2. Microbiological efficacy: it is completely unusual to consider "partially cleared" as an "effective" result. By change, no patient felt into this category.Therefore, I suggest to skip the category "partially cleared" and include this category into "not cleared". Response: the "partially cleared" category was removed. 3. To categorize "replacement" or "reinfection" also as effective therapy is sometimes done, but to my opinion not correct, because it is an "unwanted" outcome. Therefore I suggest to reorganize Table 3 as follows: Diagnosis Total Eradication Persistence Replacement/reinfection N (100%) N (%) N (%) N (%) AUC Recurrent UTI Complicated UTI Response: Table 3 was reorganized as suggested. 4. By the way: the usual terminology is for cleared-eradication and for not cleared persistence.
REVIEWER
Usually for other bacteria only the term reinfection is used, but I like the differentiation between replacement without symptoms and reinfection with symptoms. Therefore the two terms should be used, but could be summarized in the table ( or not, whatever the authors like better). Response: The term "cleared" was replaced with "eradication" and "not cleared" with " persistence", as suggested. 5. As limitation of the study it should also be mentioned that the study is not controlled. All in all, the study is well performed and presented. Response: The fact that the study was uncontrolled is now mentioned in the Discussion section, as a limitation of the study: "Another shortcoming of the study is the lack of a control group. This is due to the fact that our primary objective was to evaluate clinical, microbiological and overall efficacy of fosfomycin tromethamine, an antibiotic which is widely used abroad, but less in China, for the treatment of urinary tract infection."
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